Humanised xenograft models of bone metastasis revisited: Novel insights into species-specific mechanisms of cancer cell osteotropism

Cancer and Metastasis Reviews

Volumn 32, Issue 1-2, 2013, Pages 129-145

  Holzapfel, Boris Michael ^a,b   Thibaudeau, Laure ^a   Hesami, Parisa ^a   Taubenberger, Anna ^c   Holzapfel, Nina Pauline ^a   Mayer Wagner, Susanne ^d   Power, Carl ^e   Clements, Judith ^a,f   Russell, Pamela ^a,f   Hutmacher, Dietmar Werner ^a,g,h  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^g GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bone graft; Bone metastasis; Haematopoiesis; Humanised; Xenograft model

Indexed keywords

GROWTH FACTOR; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; BONE ATROPHY; BONE GRAFT; BONE METASTASIS; BONE RADIOGRAPHY; CANCER CELL CULTURE; CANCER CELL OSTEOTROPISM; CANCER PROGNOSIS; CANCER STAGING; CELL ISOLATION; CELL PROLIFERATION; CELL THERAPY; CLINICAL FEATURE; DISEASE MARKER; GENETIC ASSOCIATION; HEMATOPOIETIC CELL; HISTOPATHOLOGY; IMMUNOCOMPROMISED PATIENT; ISOGRAFT; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY; TISSUE ENGINEERING; TRANSGENICS; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; MICE; SPECIES SPECIFICITY;

EID: 84878114431     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9437-5     Document Type: Article

References (108)

1. Brown, J. E., Neville-Webbe, H., & Coleman, R. E. (2004). The role of bisphosphonates in breast and prostate cancers. Endocrine-Related Cancer, 11, 207-224.
2. Fizazi, K., Albiges, L., Massard, C., et al. (2012). Novel and bone-targeted agents for CRPC. Annals of Oncology, 23(Suppl 10), x264-x267. doi: 10.1093/annonc/mds353.
3. Mackiewicz-Wysocka, M., Pankowska, M., & Wysocki, P. J. (2012). Progress in the treatment of bone metastases in cancer patients. Expert Opinion on Investigational Drugs, 21, 785-795. doi: 10.1517/13543784.2012.679928.
4. Wong, M. H., Stockler, M. R., & Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews, 2, CD003474. doi: 10.1002/14651858.CD003474.pub3.
5. Hutmacher, D. W. (2010). Biomaterials offer cancer research the third dimension. Nature Materials, 9, 90-93. doi: 10.1038/nmat2619.
6. Rosol, T. J., Tannehill-Gregg, S. H., LeRoy, B. E., et al. (2003). Animal models of bone metastasis. Cancer, 97, 748-757. doi: 10.1002/cncr.11150.
7. Welch, D. R. (1997). Technical considerations for studying cancer metastasis in vivo. Clinical & Experimental Metastasis, 15, 272-306.
8. Goldstein, R. H., Weinberg, R. A., & Rosenblatt, M. (2010). Of mice and (wo)men: mouse models of breast cancer metastasis to bone. Journal of Bone and Mineral Research, 25, 431-436. doi: 10.1002/jbmr.68.
9. Singh, A. S., & Figg, W. D. (2005). In vivo models of prostate cancer metastasis to bone. Journal of Urology, 174, 820-826. doi: 10.1097/01.ju. 0000169133.82167.aa.
10. Richmond, A., & Su, Y. (2008). Mouse xenograft models vs GEM models for human cancer therapeutics. Disease Models & Mechanisms, 1, 78-82. doi: 10.1242/dmm.000976.
11. Kuperwasser, C., Dessain, S., Bierbaum, B. E., et al. (2005). A mouse model of human breast cancer metastasis to human bone. Cancer Research, 65, 6130-6138. doi: 10.1158/0008-5472.CAN-04-1408.
12. Nemeth, J. A., Harb, J. F., Barroso, U., Jr., et al. (1999). Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Research, 59, 1987-1993.
13. Yonou, H., Yokose, T., Kamijo, T., et al. (2001). Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Research, 61, 2177-2182.
14. Xia, T. S., Wang, G. Z., Ding, Q., et al. (2012). Bone metastasis in a novel breast cancer mouse model containing human breast and human bone. Breast Cancer Research and Treatment, 132, 471-486. doi: 10.1007/s10549-011-1496-0.
15. Kuperwasser, C., Chavarria, T., Wu, M., et al. (2004). Reconstruction of functionally normal and malignant human breast tissues in mice. Proceedings of the National Academy of Sciences of the United States of America, 101, 4966-4971. doi: 10.1073/pnas.0401064101.
16. Ganick, D. J., Sarnwick, R. D., Shahidi, N. T., et al. (1980). Inability of intravenously injected monocellular suspensions of human bone marrow to establish in the nude mouse. International Archives of Allergy and Applied Immunology, 62, 330-333.
17. Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007). Humanized mice in translational biomedical research. Nature Reviews Immunology, 7, 118-130. doi: 10.1038/nri2017.
18. Bosma, G. C., Custer, R. P., & Bosma, M. J. (1983). A severe combined immunodeficiency mutation in the mouse. Nature, 301, 527-530.
19. Kyoizumi, S., Baum, C. M., Kaneshima, H., et al. (1992). Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood, 79, 1704-1711.
20. Greiner, D. L., Hesselton, R. A., & Shultz, L. D. (1998). SCID mouse models of human stem cell engraftment. Stem Cells, 16, 166-177. doi: 10.1002/stem.160166.
21. Shultz, L. D., Schweitzer, P. A., Christianson, S. W., et al. (1995). Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. Journal of Immunology, 154, 180-191.
22. Boynton, E., Aubin, J., Gross, A., et al. (1996). Human osteoblasts survive and deposit new bone when human bone is implanted in SCID mouse. Bone, 18, 321-326.
23. Christianson, S. W., Greiner, D. L., Schweitzer, I. B., et al. (1996). Role of natural killer cells on engraftment of human lymphoid cells and on metastasis of human T-lymphoblastoid leukemia cells in C57BL/6J-scid mice and in C57BL/6J-scid bg mice. Cellular Immunology, 171, 186-199. doi: 10.1006/cimm.1996.0193.
24. Prochazka, M., Gaskins, H. R., Shultz, L. D., et al. (1992). The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proceedings of the National Academy of Sciences of the United States of America, 89, 3290-3294.
25. Meyerrose, T. E., Herrbrich, P., Hess, D. A., et al. (2003). Immune-deficient mouse models for analysis of human stem cells. Biotechniques, 35, 1262-1272.
26. Nakamura, Y., Ito, M., Yamamoto, T., et al. (2005). Engraftment of NOD/SCID/gammac(null) mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukaemia. British Journal of Haematology, 130, 51-57. doi: 10.1111/j.1365-2141.2005.05578.x.
27. Shultz, L. D., Lyons, B. L., Burzenski, L. M., et al. (2005). Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. Journal of Immunology, 174, 6477-6489.
28. Ishikawa, F., Yasukawa, M., Lyons, B., et al. (2005). Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice. Blood, 106, 1565-1573. doi: 10.1182/blood-2005-02-0516.
29. Ito, R., Takahashi, T., Katano, I., et al. (2012). Current advances in humanized mouse models. Cellular and molecular immunology, 9, 208-214. doi: 10.1038/cmi.2012.2.
30. Shultz, L. D., Saito, Y., Najima, Y., et al. (2010). Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 107, 13022-13027. doi: 10.1073/pnas.1000475107.
31. Shtivelman, E., & Namikawa, R. (1995). Species-specific metastasis of human tumor cells in the severe combined immunodeficiency mouse engrafted with human tissue. Proceedings of the National Academy of Sciences of the United States of America, 92, 4661-4665.
32. Banerjee, S., Hussain, M., Wang, Z., et al. (2007). In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Research, 67, 3818-3826. doi: 10.1158/0008-5472.CAN-06-3879.
33. Deng, X., He, G., Levine, A., et al. (2008). Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. International Journal of Cancer, 122, 209-218. doi: 10.1002/ijc.23053.
34. Nie, D., Nemeth, J., Qiao, Y., et al. (2003). Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clinical & Experimental Metastasis, 20, 657-663. doi: 10.1023/A:1027302408187.
35. Carbonell, F., Calvo, W., & Fliedner, T. M. (1982). Cellular composition of human fetal bone marrow. Histologic study in methacrylate sections. Acta Anatomica (Basel), 113, 371-375.
36. LeBien, T. W., Wormann, B., Villablanca, J. G., et al. (1990). Multiparameter flow cytometric analysis of human fetal bone marrow B cells. Leukemia, 4, 354-358.
37. Villablanca, J. G., Anderson, J. M., Moseley, M., et al. (1990). Differentiation of normal human pre-B cells in vitro. The Journal of Experimental Medicine, 172, 325-334.
38. Christensen, R. D., Harper, T. E., & Rothstein, G. (1986). Granulocyte-macrophage progenitor cells in term and preterm neonates. Journal of Pediatrics, 109, 1047-1051.
39. Emerson, S. G., Thomas, S., Ferrara, J. L., et al. (1989). Developmental regulation of erythropoiesis by hematopoietic growth factors: analysis on populations of BFU-E from bone marrow, peripheral blood, and fetal liver. Blood, 74, 49-55.
40. Ikuta, K., Kina, T., MacNeil, I., et al. (1990). A developmental switch in thymic lymphocyte maturation potential occurs at the level of hematopoietic stem cells. Cell, 62, 863-874.
41. Goya, M., Miyamoto, S., Nagai, K., et al. (2004). Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Research, 64, 6252-6258. doi: 10.1158/0008-5472.CAN-04-0919.
42. Ling, L. J., Wang, S., Liu, X. A., et al. (2008). A novel mouse model of human breast cancer stem-like cells with high CD44 + CD24-/lower phenotype metastasis to human bone. Chinese Medical Journal, 121, 1980-1986.
43. Sangai, T., Fujimoto, H., Miyamoto, S., et al. (2008). Roles of osteoclasts and bone-derived IGFs in the survival and growth of human breast cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Clinical & Experimental Metastasis, 25, 401-410. doi: 10.1007/s10585-008-9144-8.
44. Yang, W., Lam, P., Kitching, R., et al. (2007). Breast cancer metastasis in a human bone NOD/SCID mouse model. Cancer Biology & Therapy, 6, 1289-1294.
45. Yonou, H., Ochiai, A., Goya, M., et al. (2004). Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate, 58, 406-413. doi: 10.1002/pros.10349.
46. Lam, P., Yang, W., Amemiya, Y., et al. (2009). A human bone NOD/SCID mouse model to distinguish metastatic potential in primary breast cancers. Cancer Biology & Therapy, 8, 1010-1017.
47. Liu, S., Goldstein, R. H., Scepansky, E. M., et al. (2009). Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Research, 69, 8742-8751. doi: 10.1158/0008-5472.CAN-09-1541.
48. Amemiya, Y., Yang, W., Benatar, T., et al. (2011). Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Research and Treatment, 126, 373-384. doi: 10.1007/s10549-010-0921-0.
49. Murphy, W. J., Kumar, V., & Bennett, M. (1987). Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. The Journal of Experimental Medicine, 165, 1212-1217.
50. Heike, Y., Ohira, T., Takahashi, M., et al. (1995). Long-term human hematopoiesis in SCID-hu mice bearing transplanted fragments of adult bone and bone marrow cells. Blood, 86, 524-530.
51. Sandhu, J. S., Clark, B. R., Boynton, E. L., et al. (1996). Human hematopoiesis in SCID mice implanted with human adult cancellous bone. Blood, 88, 1973-1982.
52. Hubin, F., Humblet, C., Belaid, Z., et al. (2004). Maintenance of functional human cancellous bone and human hematopoiesis in NOD/SCID mice. Cell Transplantation, 13, 823-831.
53. Kaplan, R. N., Rafii, S., & Lyden, D. (2006). Preparing the "soil": the premetastatic niche. Cancer Research, 66, 11089-11093. doi: 10.1158/0008-5472.CAN-06-2407.
54. Kaplan, R. N., Riba, R. D., Zacharoulis, S., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820-827. doi: 10.1038/nature04186.
55. Shiozawa, Y., Pedersen, E. A., Havens, A. M., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121, 1298-1312. doi: 10.1172/JCI43414.
56. Kahn, D., Weiner, G. J., Ben-Haim, S., et al. (1994). Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood, 83, 958-963.
57. Roodman, G. D. (2004). Mechanisms of bone metastasis. The New England Journal of Medicine, 350, 1655-1664. doi: 10.1056/NEJMra030831.
58. Bianco, P. (2011). Bone and the hematopoietic niche: a tale of two stem cells. Blood, 117, 5281-5288. doi: 10.1182/blood-2011-01-315069.
59. Xia, T. S., Wang, J., Yin, H., et al. (2010). Human tissue-specific microenvironment: an essential requirement for mouse models of breast cancer. Oncology Reports, 24, 203-211.
60. Waitches, G., Zawin, J. K., & Poznanski, A. K. (1994). Sequence and rate of bone marrow conversion in the femora of children as seen on MR imaging: are accepted standards accurate? AJR. American Journal of Roentgenology, 162, 1399-1406.
61. Atkinson, H. R. (1962). Bone marrow distribution as a factor in estimating radiation to the blood-forming organ: a survey of present knowledge. Journal of the College of Radiologists of Australasia, 6, 149-154.
62. Ellis, R. E. (1961). The distribution of active bone marrow in the adult. Physics in Medicine and Biology, 5, 255-258.
63. Hayman, J. A., Callahan, J. W., Herschtal, A., et al. (2011). Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging. International Journal of Radiation Oncology, Biology, Physics, 79, 847-852. doi: 10.1016/j.ijrobp.2009.11.040.
64. Laor, T., & Jaramillo, D. (2009). MR imaging insights into skeletal maturation: what is normal? Radiology, 250, 28-38. doi: 10.1148/radiol. 2501071322.
65. Hutmacher, D. W., Loessner, D., Rizzi, S., et al. (2010). Can tissue engineering concepts advance tumor biology research? Trends in Biotechnology, 28, 125-133. doi: 10.1016/j.tibtech.2009.12.001.
66. Moreau, J. E., Anderson, K., Mauney, J. R., et al. (2007). Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Research, 67, 10304-10308. doi: 10.1158/0008-5472.CAN- 07-2483.
67. Schuster, J., Zhang, J., & Longo, M. (2006). A novel human osteoblast-derived severe combined immunodeficiency mouse model of bone metastasis. Journal of Neurosurgery: Spine, 4, 388-391. doi: 10.3171/spi.2006.4.5.388.
68. Hutmacher, D. W., Horch, R. E., Loessner, D., et al. (2009). Translating tissue engineering technology platforms into cancer research. Journal of Cellular and Molecular Medicine, 13, 1417-1427. doi: 10.1111/j.1582-4934.2009. 00853.x.
69. Goldstein, R. H., Reagan, M. R., Anderson, K., et al. (2010). Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Research, 70, 10044-10050. doi: 10.1158/0008-5472.CAN-10- 1254.
70. Moreau, J., Anderson, K. M., Mauney, J. R., et al. (2007). Studies of osteotropism on both sides of the breast cancer-bone interaction. Annals of the New York Academy of Sciences, 1117, 328-344. doi: 10.1196/annals.1402.003.
71. Yu, H., VandeVord, P. J., Mao, L., et al. (2009). Improved tissue-engineered bone regeneration by endothelial cell mediated vascularization. Biomaterials, 30, 508-517. doi: 10.1016/j.biomaterials.2008.09. 047.
72. Holzapfel, B. M., Reichert, J. C., Schantz, J. T., et al. (2012). How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev. doi: 10.1016/j.addr.2012.07.009.
73. Hutmacher, D. W., Schantz, J. T., Lam, C. X., et al. (2007). State of the art and future directions of scaffold-based bone engineering from a biomaterials perspective. Journal of Tissue Engineering and Regenerative Medicine, 1, 245-260. doi: 10.1002/term.24.
74. Probst, F. A., Hutmacher, D. W., Muller, D. F., et al. (2010). Calvarial reconstruction by customized bioactive implant. Handchirurgie, Mikrochirurgie, Plastische Chirurgie, 42, 369-373. doi: 10.1055/s-0030-1248310.
75. Reichert, J. C., Cipitria, A., Epari, D. R., et al. (2012). A tissue engineering solution for segmental defect regeneration in load-bearing long bones. Science Translational Medicine, 4, 141ra193. doi: 10.1126/scitranslmed. 3003720.
76. Reichert, J. C., Epari, D. R., Wullschleger, M. E., et al. (2010). Establishment of a preclinical ovine model for tibial segmental bone defect repair by applying bone tissue engineering strategies. Tissue Engineering. Part B, Reviews, 16, 93-104. doi: 10.1089/ten.TEB.2009.0455.
77. Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews. Cancer, 3, 453-458. doi: 10.1038/nrc1098.
78. Zeidman, I., & Buss, J. M. (1952). Transpulmonary passage of tumor cell emboli. Cancer Research, 12, 731-733.
79. Fidler, I. J. (2001). Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surgical Oncology Clinics of North America, 10, 257-269. vii-viiii.
80. Halperin, E. C., Schmidt-Ulrich, R. K., Perez, C. A., & Brady, L. W. (2004). The discipline of radiation oncology. In C. A. Perez, L. W. Brady, E. C. Halperin, & R. K. Schmidt-Ulrich (Eds.), Hrsg. Principles and Practice of Radiation Oncology (4th ed., pp. 1-95). Philadelphia: Lippincott Williams & Wilkins.
81. Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet, 1, 571-573.
82. Bauerle, T., Adwan, H., Kiessling, F., et al. (2005). Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. International Journal of Cancer, 115, 177-186. doi: 10.1002/ijc.20840.
83. Bauerle, T., Peterschmitt, J., Hilbig, H., et al. (2006). Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. International Journal of Oncology, 28, 573-583.
84. Neudert, M., Fischer, C., Krempien, B., et al. (2003). Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. International Journal of Cancer, 107, 468-477. doi: 10.1002/ijc.11397.
85. Halpern, J., Lynch, C. C., Fleming, J., et al. (2006). The application of a murine bone bioreactor as a model of tumor: bone interaction. Clinical & Experimental Metastasis, 23, 345-356. doi: 10.1007/s10585-006-9044-8.
86. Tamura, H., Ishii, S., Ikeda, T., et al. (1999). The relationship between urinary pyridinoline, deoxypyridinoline and bone metastasis in a rat breast cancer model. Breast Cancer, 6, 23-28.
87. Tamura, H., Ishii, S., Ikeda, T., et al. (1996). Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model. Surgical Oncology, 5, 141-147.
88. Mayevski, A. (1978). Ischemia in the brain: the effects of carotid artery ligation and decapitation on the energy state of the awake and anesthetized rat. Brain Research, 140, 217-230.
89. Yoneda, T., Williams, P. J., Hiraga, T., et al. (2001). A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. Journal of Bone and Mineral Research, 16, 1486-1495. doi: 10.1359/jbmr.2001.16. 8.1486.
90. Goodale, D., Phay, C., Postenka, C. O., et al. (2009). Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry. Part A, 75, 344-355. doi: 10.1002/cyto.a.20657.
91. Havens, A. M., Pedersen, E. A., Shiozawa, Y., et al. (2008). An in vivo mouse model for human prostate cancer metastasis. Neoplasia, 10, 371-380.
92. Thalmann, G. N., Anezinis, P. E., Chang, S. M., et al. (1994). Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Research, 54, 2577-2581.
93. Tsingotjidou, A. S., Ahluwalia, R., Zhang, X., et al. (2003). A metastatic human prostate cancer model using intraprostatic implantation of tumor produced by PC-3 neolacZ transfected cells. International Journal of Oncology, 23, 1569-1574.
94. Al Nakouzi, N., Bawa, O., Le Pape, A., et al. (2012). The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer. Neoplasia, 14, 376-387.
95. An, Z., Wang, X., Geller, J., et al. (1998). Surgical orthotopic implantation allows high lung and lymph node metastatic expression of human prostate carcinoma cell line PC-3 in nude mice. Prostate, 34, 169-174.
96. Rembrink, K., Romijn, J. C., van der Kwast, T. H., et al. (1997). Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate, 31, 168-174.
97. Nemeth, J. A., Yousif, R., Herzog, M., et al. (2002). Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. Journal of the National Cancer Institute, 94, 17-25.
98. Yonou, H., Kanomata, N., Goya, M., et al. (2003). Osteoprotegerin/ osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Research, 63, 2096-2102.
99. Sutton, E. J., Henning, T. D., Pichler, B. J., et al. (2008). Cell tracking with optical imaging. European Radiology, 18, 2021-2032. doi: 10.1007/s00330-008-0984-z.
100. Butler, T. P., & Gullino, P. M. (1975). Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Research, 35, 512-516.
101. Weiss, L. (1990). Metastatic inefficiency. Advances in Cancer Research, 54, 159-211.
102. Welch, D. R. (2006). Do we need to redefine a cancer metastasis and staging definitions? Breast Disease, 26, 3-12.
103. Tentler, J. J., Tan, A. C., Weekes, C. D., et al. (2012). Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews. Clinical Oncology, 9, 338-350. doi: 10.1038/nrclinonc.2012.61.
104. Daniel, V. C., Marchionni, L., Hierman, J. S., et al. (2009). A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Research, 69, 3364-3373. doi: 10.1158/0008-5472.CAN-08-4210.
105. Hillen, F., & Griffioen, A. W. (2007). Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Reviews, 26, 489-502. doi: 10.1007/s10555-007-9094-7.
106. Pantel, K., & Alix-Panabieres, C. (2010). Circulating tumour cells in cancer patients: challenges and perspectives. Trends in Molecular Medicine, 16, 398-406. doi: 10.1016/j.molmed.2010.07.001.
107. Nicolson, G. L. (1988). Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochimica et Biophysica Acta, 948, 175-224.
108. van der Pluijm, G. (2011). Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone, 48, 37-43. doi: 10.1016/j.bone.2010.07.023.